Abstract
Over the recent years, drug therapy for liver diseases has moved from symptomatic to targeted therapy. It was also shown that the crucial factor in the progression of any liver disease to an advanced stage is the fibrosing process.
Supportive or complementary therapy should be targeted to slow down or reverse the process of liver fibrosis. Abandoning the wide use of hepatoprotective agents is in line with this approach.
Hepatoprotective agents are a family of diverse drugs that may be effective in slowing down some pathological processes in acute and chronic liver diseases. Such effects were experimentally demonstrated for many agents but their usability in clinical practice is very limited.